CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

Inclusion Criteria

• •≥ 18 years of age on the day of signing informed consent.
• •Karnofsky performance \>70%
• •Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.
• •Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.
• •Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.
• •Must be within Day-10 thru Day+28 days of planned HSCT at the time of enrollment.
• •Be able to comply with medical recommendations or follow-up.
• •Has adequate organ functions determined by
• •1. Serum creatinine clearance ≥50 ml/min (calculated with Cockroft-Gault formula).
• •2. Bilirubin ≤1.5 mg/dl except for Gilbert's disease.
• •3. ALT or AST ≤200 IU/ml for adults.
• •4. Conjugated (direct) bilirubin \< 2x upper limit of normal.
• •5. Left ventricular ejection fraction ≥40%.
• •6. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.